prikaz prve stranice dokumenta Substitution of doxorubicin with etoposide in the treatment of lymphomas
  Download
PDF 423.74 KB
master's thesis
Substitution of doxorubicin with etoposide in the treatment of lymphomas
Zagreb: University of Zagreb, School of Medicine, 2017. urn:nbn:hr:105:657164
Terry, Meredith Olivia
University of Zagreb
School of Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Terry, M. O. (2017). Substitution of doxorubicin with etoposide in the treatment of lymphomas (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:657164

Terry, Meredith Olivia. "Substitution of doxorubicin with etoposide in the treatment of lymphomas." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:657164

Terry, Meredith Olivia. "Substitution of doxorubicin with etoposide in the treatment of lymphomas." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:657164

Terry, M. O. (2017). 'Substitution of doxorubicin with etoposide in the treatment of lymphomas', Master's thesis, University of Zagreb, School of Medicine, accessed 20 April 2024, https://urn.nsk.hr/urn:nbn:hr:105:657164

Terry MO. Substitution of doxorubicin with etoposide in the treatment of lymphomas [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2017 [cited 2024 April 20] Available at: https://urn.nsk.hr/urn:nbn:hr:105:657164

M. O. Terry, "Substitution of doxorubicin with etoposide in the treatment of lymphomas", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:105:657164

Metadata
TitleSubstitution of doxorubicin with etoposide in the treatment of lymphomas
Title (croatian)Zamjena doksorubicina etopozidom u liječenju limfoma
AuthorMeredith Olivia Terry
MentorIgor Aurer (mentor)
Committee memberIgor Aurer (predsjednik povjerenstva)
Committee memberRadovan Vrhovac (član povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
Zagreb
Defense date and country2017-07-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract
PURPOSE: This study set out to examine the survival and progression-free outcomes in aggressive lymphoma patients receiving (R)CEOP therapy due to contraindications for anthracycline therapy. Toxicities that developed were also evaluated and reported. ----- PATIENTS & METHODS: Hospital records were searched for patients who received (R)CEOP in >50% of chemotherapy cycles. A total of 44 patients were included from KBC Zagreb, with 33 B cell lymphoma and 11 T cell lymphoma patients. Data was analyzed to evaluate survival, risk factors, and toxicities. ----- RESULTS: Patients were followed up a median of 30.3 months. The 5 year overall survival rate was approximately 48% and event-free survival 40%. It was found that elevated LDH at diagnosis and age >70 years are poor prognostic factors, having a statistically significant correlation to poorer overall survival. All other risk and prognostic factors were not found to have a statistically significant impact on survival. The most commonly encountered toxicities were cytopenias and infections (34% and 34%). ----- CONCLUSION: (R)CEOP therapy is generally well-tolerated in patients with co-morbidities that preclude traditional anthracycline therapy. Elevated LDH and advanced age are poor prognostic factors for survival. This study found no statistically significant difference according to cell of origin in DLBCL patients and survival outcomes.
Abstract (croatian)
CILJ: Ovo istraživanje ispitalo je ukupno preživljavanje i preživljavanje bez događaja bolesnika s agresivnim limfomima koji su primali (R)CEOP terapiju zbog kontraindikacija za liječenje antraciklinima. Ispitana je i toksičnost ovog protokola. ----- BOLESNICI I METODE: Iz bolničkih povijesti bolesti su identificirani bolesnici koji su primali (R)CEOP u >50% ciklusa kemoterapije. U istraživanje je uključeno ukupno 44 bolesnika liječenih u KBC Zagrebu, 33 s B-staničnim i 11 s limfomima T stanice. Na temelju prikupljenih podataka analizirani su preživljavanje, čimbenici rizika i toksičnost. ----- REZULTATI: Medijan praćenja iznosio je 30,3 mjeseci. Petogodišnje preživljavanje iznosilo je 48%, a preživljavanje bez događaja 40%. Povišen LDH pri dijagnozi i dob >70 godina bili su statistički značajni nepovoljni prognostički faktori koji su korelirali s lošijim preživljavanjem. Za sve ostale rizike i prognostičke čimbenike nije utvrđeno da imaju statistički značajan utjecaj na preživljavanje. Najčešće toksičnosti bile su citopenije i infekcije (34% i 34%). ----- ZAKLJUČAK: Bolesnici s komorbiditetima koji onemogućavaju uobičajeno liječenje antraciklinima obično dobro podnose (R)CEOP. Povišen LDH i starija dob su prediktori lošijeg ishoda. U ovoj studiji nismo našli da postoji statistički značajna razlika u preživljavanju između bolesnika s DLBCL različitog staničnog porijekla.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:105:657164
Study programmeTitle: Medicine (in English language)
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2018-04-25 07:27:06